<DOC>
	<DOCNO>NCT00362765</DOCNO>
	<brief_summary>Double-blind , randomize placebo-controlled study type 2 diabetes dyslipidemic patients.Patients randomize one four treatment arm 16 week : placebo , fenofibrate , metformin , metformin fenofibrate combination .</brief_summary>
	<brief_title>Fenofibrate Metformin Insulin Sensitivity Type 2 Diabetics Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patients type 2 diabetes mellitus dyslipidemia . Type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Hyperinsulinemic</keyword>
	<keyword>Clamp</keyword>
	<keyword>Metformin</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>